AstraZeneca?s $4 billion Acerta deal endorsed by orphan drug status
 

AstraZeneca?s $4 billion Acerta deal endorsed by orphan drug status
LONDON (Reuters) - AstraZeneca's bold move to buy 55 percent of privately held biotech firm Acerta Pharma for $4 billion in December has been vindicated, at least in part, by the award of special "orphan" status to the key experimental drug involved.
http://i0.wp.com/reuters.us.feedspor...f?resize=1%2C1http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...7I:F7zBnMyn0Lo http://feeds.feedburner.com/~ff/reut...7I:V_sGLiPBpWU
http://feeds.feedburner.com/~r/reute...~4/nGRAZrh9sgA